查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1953402

代謝分析市場 - 全球產業規模、佔有率、趨勢、機會及預測（按產品類型、應用、技術、最終用途、地區和競爭格局分類，2021-2031年）

Metabolism Assays Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Application (Diagnostics, Research), By Technology, By End-use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球代謝檢測市場預計將從 2025 年的 17.1 億美元成長到 2031 年的 27.2 億美元，複合年成長率達到 8.02%。

這些檢測方法用於測量代謝活性，例如酶動力學和代謝物濃度，是評估細胞生物能量學和生理健康的重要定量分析程序。該市場的主要成長要素是慢性代謝疾病盛行率的不斷上升，以及由此帶來的藥物研發投入的增加，旨在開發新的治療方法。根據世界肥胖聯盟2024年的預測，到2035年，肥胖成年人的數量預計將達到15.3億，凸顯了對有效代謝篩檢工具的迫切需求。這也推動了對用於治療代謝症候群的藥物研發中可靠方法的需求。

市場概覽
預測期 2027-2031
市場規模：2025年 17.1億美元
市場規模：2031年 27.2億美元
複合年成長率：2026-2031年 8.02%
成長最快的細分市場 診斷
最大的市場 北美洲

儘管市場成長前景良好，但由於先進檢測技術高成本且技術複雜，仍面臨許多障礙。多重分析儀和試劑需要大量資金投入和專業人員，這限制了預算有限的小規模實驗室和學術機構的應用。這種經濟障礙，加上複雜代謝組學數據解讀的難度，阻礙了這些檢測方法在資源匱乏地區的廣泛應用，減緩了全球市場的整體擴張。

市場促進因素

全球慢性代謝疾病（尤其是糖尿病）盛行率的快速成長是代謝檢測市場的主要驅動力。隨著患者數量的增加，製藥公司和學術研究人員正優先開發針對代謝路徑的治療方法，從而增加了對標靶檢驗和先導化合物最佳化的檢測應用。需要長期血糖控制管理的人群數量不斷增加，也推動了這一趨勢，從而對精準的診斷和監測工具產生了持續的需求。根據發表在2024年11月《柳葉刀》雜誌上題為「全球糖尿病盛行率不平等」的分析報告，全球成年糖尿病患者人數將達到8.28億，這一數字迫切需要快速擴展代謝篩檢能力。

此外，製藥和生技公司不斷增加的研發投入正在推動市場擴張，因為相關人員希望從盈利的抗肥胖和糖尿病治療領域獲利。各公司正大力投資高通量篩檢和代謝譜分析，以識別新的生物標記和候選治療藥物，而這需要先進的檢測平台。例如，禮來公司在其2024年2月發布的2023年度報告中披露，其研發支出增加至93.1億美元，主要得益於對代謝功能障礙治療藥物的後期研發投入。這項投資與整個產業的趨勢相符，即監管部門的核准會刺激對檢測技術的再投資。美國食品藥物管理局（FDA）在2024年核准了55種新分子實體（NME），與上年度相比有所增加，這創造了一個高度依賴代謝數據的創新環境。

市場挑戰

先進檢測技術固有的高昂成本和技術複雜性，對全球代謝檢測市場的成長構成了重大障礙。這些定量分析程序所需的精密多重分析設備和試劑需要大量的資金投入，直接限制了其在成本敏感型環境中的應用。小規模研究機構和學術機構對於市場滲透至關重要，但它們往往缺乏購買和維護此類昂貴基礎設施的財力。此外，解讀複雜代謝組學數據需要專業人員，這造成了技能缺口，進一步限制了這些檢測方法在發展中地區的應用。

這種資金和技術上的壟斷阻礙了市場成長，因為高通量篩檢工具的使用權主要集中在財力雄厚的大型製藥公司手中，限制了其在更廣泛的科學界的普及應用。這些資金限制的影響在近期的投資趨勢中顯而易見：根據馬薩諸塞州生物技術委員會（MassBio）的數據，2025年上半年當地生物製藥公司的創業投資金額較2024年同期下降了17.1%。資金短缺加劇了這項挑戰，迫使實驗室推遲升級到先進的檢測平台，直接減緩了全球市場的收入成長。

市場趨勢

人工智慧驅動的數據分析的整合正在從根本上改變全球代謝檢測市場，它消除了代謝譜分析中複雜數據解讀的瓶頸。現代檢測方法產生的高維度資料集需要先進的機器學習演算法來檢測傳統統計方法常常忽略的細微生物標記模式。這項技術的整合加速了先導化合物的識別，並提高了代謝反應預測的準確性，從而提升了藥物研發工作流程的效率。根據英偉達 (NVIDIA) 於 2025 年 7 月開展的「醫療保健和生命科學領域人工智慧現狀：2025 年趨勢」調查，超過 80% 的醫療保健和生命科學專業人士表示，他們的機構因採用人工智慧而獲得了收入成長，這證實了這些運算工具的商業性和營運價值。

同時，晶片器官和3D培養模型的出現標誌著藥物研發正朝著更貼近生理實際的測試環境邁進，從而減少對動物模型的依賴。動物模型往往無法準確預測藥物對人體的代謝毒性。這些微生理系統能夠模擬人體組織的動態生化微環境，從而更準確地評估藥物代謝和生物能量學。製造商正在加速採用將這些模型與自動化技術結合的整合平台，以支援工業規模的篩檢。例如，《藥物發現新聞》（Drug Discovery News）在2025年10月報道，CN Bio宣布推出其「PhysioMimix Core」系統。該系統是一個一體化的晶片器官平台，能夠同時對多達288個樣本進行高通量篩檢，展現了擴充性。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章：全球代謝分析市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品類型（檢測試劑盒/試劑、儀器/分析設備）
    • 透過應用（診斷（糖尿病、肥胖、癌症、心血管疾病等）、研究）
    • 依技術（比色分析、螢光分析、光譜分析）
    • 按最終用戶（醫院、診斷檢查室、製藥和生物製藥公司、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美代謝分析市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲代謝分析市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區代謝分析市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲代謝分析市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲代謝分析市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球代謝分析市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Merck KGaA
  • Thermo Fisher Scientific, Inc.
  • Abcam Limited
  • Agilent Technologies, Inc.
  • Promega Corporation
  • Kaneka Eurogentec SA
  • RayBiotech Life, Inc.
  • Sartorius AG
  • Elabscience Bionovation Inc.
  • BMG LABTECH GmbH

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23731

The Global Metabolism Assays Market is projected to expand from USD 1.71 Billion in 2025 to USD 2.72 Billion by 2031, achieving a compound annual growth rate of 8.02%. These assays serve as quantitative analytical procedures essential for measuring metabolic activities, such as enzyme kinetics and metabolite concentrations, to evaluate cellular bioenergetics and physiological health. The market is primarily driven by the rising prevalence of chronic metabolic disorders and the consequent intensification of pharmaceutical research and development efforts aimed at creating novel therapeutic interventions. According to the World Obesity Federation's 2024 projections, the number of adults living with obesity is expected to reach 1.53 billion by 2035, highlighting the critical need for effective metabolic screening tools and fueling the demand for robust methods in drug discovery to treat metabolic syndromes.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.71 Billion
Market Size 2031USD 2.72 Billion
CAGR 2026-20318.02%
Fastest Growing SegmentDiagnostics
Largest MarketNorth America

Despite this positive growth outlook, the market encounters significant obstacles due to the high costs and technical complexities associated with advanced assay technologies. Multiplexing instruments and reagents necessitate substantial capital investment and specialized personnel, which restricts their adoption in smaller research laboratories and academic institutions with limited budgets. This financial hurdle, combined with the difficulty of interpreting complex metabolomic data, hampers the widespread implementation of these assays in resource-constrained regions, thereby slowing the overall expansion of the global market.

Market Driver

The surging global prevalence of chronic metabolic diseases, particularly diabetes, acts as the primary catalyst for the metabolism assays market. As patient populations grow, pharmaceutical companies and academic researchers are prioritizing the development of therapeutics that target metabolic pathways, leading to increased usage of assays for target validation and lead optimization. This trend is underscored by the rising number of individuals requiring long-term glucose regulation management, creating a continuous demand for precise diagnostic and monitoring tools. According to an analysis in The Lancet from November 2024, titled 'Global inequalities in diabetes prevalence', the global number of adults living with diabetes has reached 828 million, a figure that necessitates the rapid scaling of metabolic screening capabilities.

Furthermore, increasing research and development investment by pharmaceutical and biotechnology firms reinforces market expansion as stakeholders aim to capitalize on the lucrative anti-obesity and diabetes drug sectors. Companies are channeling significant capital into high-throughput screening and metabolic profiling to identify novel biomarkers and therapeutic candidates, which requires advanced assay platforms. For instance, Eli Lilly and Company reported in their February 2024 '2023 Annual Report' that research and development expenses rose to $9.31 billion, largely driven by late-stage investments in metabolic dysfunction treatments. This financial commitment aligns with broader industry trends where regulatory success drives reinvestment in assay technologies, as evidenced by the U.S. Food and Drug Administration's confirmation in 2024 of 55 novel molecular entity approvals in the preceding year, reflecting an innovation environment heavily dependent on metabolic data.

Market Challenge

The substantial cost and technical complexity inherent in advanced assay technologies present a significant barrier to the growth of the Global Metabolism Assays Market. Advanced multiplexing instruments and the necessary reagents for these quantitative analytical procedures require major capital expenditure, which directly limits their adoption in cost-sensitive environments. Smaller research laboratories and academic institutions, which are essential for broad market penetration, often lack the financial resources to procure and maintain such expensive infrastructure. Additionally, the need for specialized personnel to interpret complex metabolomic data results in a skills gap that further restricts the deployment of these assays in developing regions.

This financial and technical exclusivity hinders market growth by limiting the use of high-throughput screening tools primarily to well-funded pharmaceutical giants, thereby suppressing volume growth across the wider scientific community. The impact of these financial constraints is highlighted by recent investment trends; according to the Massachusetts Biotechnology Council (MassBio), venture capital investments in regional biopharmaceutical companies declined by 17.1% in the first half of 2025 compared to the same period in 2024. This contraction in available funding exacerbates the challenge, compelling laboratories to delay upgrades to advanced assay platforms and directly decelerating the revenue trajectory of the global market.

Market Trends

The integration of AI-driven data analytics is fundamentally transforming the Global Metabolism Assays Market by resolving the bottleneck of complex data interpretation in metabolic profiling. The high-dimensional datasets produced by modern assays demand advanced machine learning algorithms to detect subtle biomarker patterns that traditional statistical methods might overlook. This technological integration accelerates hit identification and improves the predictive accuracy of metabolic responses, thereby enhancing operational efficiency in drug discovery workflows. According to the 'State of AI in Healthcare and Life Sciences: 2025 Trends' survey by NVIDIA in July 2025, over 80% of healthcare and life sciences professionals indicated that AI adoption has increased revenue at their organizations, confirming the commercial and operational value of these computational tools.

Concurrently, the emergence of organ-on-a-chip and 3D culture models marks a significant shift toward physiologically relevant testing environments, reducing dependence on animal models that often fail to predict human metabolic toxicity. These microphysiological systems mimic the dynamic biochemical microenvironments of human tissues, enabling more accurate assessments of drug metabolism and bioenergetics. Manufacturers are increasingly introducing integrated platforms that combine these models with automation to support industrial-scale screening. For example, Drug Discovery News reported in October 2025 that CN Bio unveiled the PhysioMimix Core system, an all-in-one organ-on-a-chip platform capable of high-throughput screening for up to 288 samples simultaneously, demonstrating the scalability necessary for broader pharmaceutical adoption.

Key Market Players

  • Merck KGaA
  • Thermo Fisher Scientific, Inc.
  • Abcam Limited
  • Agilent Technologies, Inc.
  • Promega Corporation
  • Kaneka Eurogentec S.A.
  • RayBiotech Life, Inc.
  • Sartorius AG
  • Elabscience Bionovation Inc.
  • BMG LABTECH GmbH

Report Scope

In this report, the Global Metabolism Assays Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Metabolism Assays Market, By Product Type

  • Assay Kits & Reagents
  • Instruments & Analyzers

Metabolism Assays Market, By Application

  • Diagnostics (Diabetes, Obesity, Cancer, Cardiovascular diseases, Other)
  • Research

Metabolism Assays Market, By Technology

  • Colorimetry
  • Fluorimetry
  • Spectrometry

Metabolism Assays Market, By End-use

  • Hospitals
  • Diagnostic Labs
  • Pharmaceutical & biopharmaceutical companies
  • Others

Metabolism Assays Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Metabolism Assays Market.

Available Customizations:

Global Metabolism Assays Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Metabolism Assays Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Assay Kits & Reagents, Instruments & Analyzers)
    • 5.2.2. By Application (Diagnostics (Diabetes, Obesity, Cancer, Cardiovascular diseases, Other), Research)
    • 5.2.3. By Technology (Colorimetry, Fluorimetry, Spectrometry)
    • 5.2.4. By End-use (Hospitals, Diagnostic Labs, Pharmaceutical & biopharmaceutical companies, others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Metabolism Assays Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Application
    • 6.2.3. By Technology
    • 6.2.4. By End-use
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Metabolism Assays Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Technology
        • 6.3.1.2.4. By End-use
    • 6.3.2. Canada Metabolism Assays Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Technology
        • 6.3.2.2.4. By End-use
    • 6.3.3. Mexico Metabolism Assays Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Technology
        • 6.3.3.2.4. By End-use

7. Europe Metabolism Assays Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Application
    • 7.2.3. By Technology
    • 7.2.4. By End-use
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Metabolism Assays Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Technology
        • 7.3.1.2.4. By End-use
    • 7.3.2. France Metabolism Assays Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Technology
        • 7.3.2.2.4. By End-use
    • 7.3.3. United Kingdom Metabolism Assays Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Technology
        • 7.3.3.2.4. By End-use
    • 7.3.4. Italy Metabolism Assays Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Technology
        • 7.3.4.2.4. By End-use
    • 7.3.5. Spain Metabolism Assays Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By Technology
        • 7.3.5.2.4. By End-use

8. Asia Pacific Metabolism Assays Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Application
    • 8.2.3. By Technology
    • 8.2.4. By End-use
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Metabolism Assays Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Technology
        • 8.3.1.2.4. By End-use
    • 8.3.2. India Metabolism Assays Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Technology
        • 8.3.2.2.4. By End-use
    • 8.3.3. Japan Metabolism Assays Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Technology
        • 8.3.3.2.4. By End-use
    • 8.3.4. South Korea Metabolism Assays Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Technology
        • 8.3.4.2.4. By End-use
    • 8.3.5. Australia Metabolism Assays Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Technology
        • 8.3.5.2.4. By End-use

9. Middle East & Africa Metabolism Assays Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Application
    • 9.2.3. By Technology
    • 9.2.4. By End-use
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Metabolism Assays Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Technology
        • 9.3.1.2.4. By End-use
    • 9.3.2. UAE Metabolism Assays Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Technology
        • 9.3.2.2.4. By End-use
    • 9.3.3. South Africa Metabolism Assays Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Technology
        • 9.3.3.2.4. By End-use

10. South America Metabolism Assays Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Application
    • 10.2.3. By Technology
    • 10.2.4. By End-use
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Metabolism Assays Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Technology
        • 10.3.1.2.4. By End-use
    • 10.3.2. Colombia Metabolism Assays Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Technology
        • 10.3.2.2.4. By End-use
    • 10.3.3. Argentina Metabolism Assays Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Technology
        • 10.3.3.2.4. By End-use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Metabolism Assays Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Merck KGaA
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Thermo Fisher Scientific, Inc.
  • 15.3. Abcam Limited
  • 15.4. Agilent Technologies, Inc.
  • 15.5. Promega Corporation
  • 15.6. Kaneka Eurogentec S.A.
  • 15.7. RayBiotech Life, Inc.
  • 15.8. Sartorius AG
  • 15.9. Elabscience Bionovation Inc.
  • 15.10. BMG LABTECH GmbH

16. Strategic Recommendations

17. About Us & Disclaimer